HRP20161345T1 - Cd19 vezivna sredstva i njihova uporaba - Google Patents
Cd19 vezivna sredstva i njihova uporaba Download PDFInfo
- Publication number
- HRP20161345T1 HRP20161345T1 HRP20161345TT HRP20161345T HRP20161345T1 HR P20161345 T1 HRP20161345 T1 HR P20161345T1 HR P20161345T T HRP20161345T T HR P20161345TT HR P20161345 T HRP20161345 T HR P20161345T HR P20161345 T1 HRP20161345 T1 HR P20161345T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- carbocyclic
- heterocyclic
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 11
- -1 C2-C20 alkynyl Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims 2
- IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 claims 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 claims 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 claims 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 claims 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 229960005532 CC-1065 Drugs 0.000 claims 1
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical compound CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 claims 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims 1
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 claims 1
- 108010009858 Echinomycin Proteins 0.000 claims 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 108010042309 Netropsin Proteins 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 108010046713 cemadotin Proteins 0.000 claims 1
- 229950009017 cemadotin Drugs 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960005501 duocarmycin Drugs 0.000 claims 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 1
- 229930184221 duocarmycin Natural products 0.000 claims 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 claims 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 claims 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 1
- 229960001842 estramustine Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229950010131 puromycin Drugs 0.000 claims 1
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 claims 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98120607P | 2007-10-19 | 2007-10-19 | |
US1921408P | 2008-01-04 | 2008-01-04 | |
US8016908P | 2008-07-11 | 2008-07-11 | |
PCT/US2008/080373 WO2009052431A2 (en) | 2007-10-19 | 2008-10-17 | Cd19 binding agents and uses thereof |
EP08840713.5A EP2211904B1 (en) | 2007-10-19 | 2008-10-17 | Cd19 binding agents and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161345T1 true HRP20161345T1 (hr) | 2016-11-18 |
Family
ID=40568090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161345TT HRP20161345T1 (hr) | 2007-10-19 | 2016-10-14 | Cd19 vezivna sredstva i njihova uporaba |
Country Status (20)
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004316290C1 (en) | 2003-11-06 | 2012-02-02 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
AU2008230795B2 (en) | 2007-03-27 | 2014-05-29 | Bioassets, Llc | Constructs and libraries comprising antibody surrogate light chain sequences |
CL2008002085A1 (es) | 2007-07-16 | 2008-11-21 | Genentech Inc | Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b |
ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
MX2010004219A (es) | 2007-10-19 | 2010-08-09 | Seattle Genetics Inc | Agentes de enlace de cd19 y usos de los mismos. |
ES2587392T3 (es) | 2008-01-31 | 2016-10-24 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
EP2430047B1 (en) | 2009-05-13 | 2018-03-28 | i2 Pharmaceuticals, Inc. | Neutralizing molecules to influenza viruses |
CN110054692A (zh) | 2009-10-23 | 2019-07-26 | 米伦纽姆医药公司 | 抗gcc抗体分子及其相关组合物和方法 |
EA201201120A1 (ru) * | 2010-02-08 | 2013-03-29 | Эдженсис, Инк. | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 161p2f10b |
PT2542576T (pt) * | 2010-03-02 | 2016-07-14 | Seattle Genetics Inc | Métodos para rastreio de anticorpos |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
ES2711622T3 (es) | 2010-08-05 | 2019-05-06 | Seattle Genetics Inc | Inhibición de la fucosilación in vivo usando análogos de fucosa |
JP5884139B2 (ja) * | 2010-10-04 | 2016-03-15 | 国立研究開発法人理化学研究所 | Mhcクラスiiを発現する悪性腫瘍の治療薬 |
JP6121906B2 (ja) | 2010-10-22 | 2017-04-26 | シアトル ジェネティクス,インコーポレーテッド | アウリスタチン系抗体薬物複合体とPI3K−AKTmTOR経路インヒビターの間の相乗効果 |
CN103403621B (zh) | 2010-12-23 | 2015-11-25 | 尤利塔股份公司 | 用于在大面积上产生纳米结构的系统和方法 |
DK2654780T3 (en) | 2010-12-23 | 2017-04-10 | Janssen Biotech Inc | ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS |
SI2694111T1 (sl) * | 2011-04-01 | 2016-10-28 | Wyeth Llc | Konjugati protitelo-zdravilo |
US8685383B2 (en) | 2011-06-10 | 2014-04-01 | Mersana Therapeautics, Inc. | Protein-polymer-drug conjugates |
CA2842860A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies, Llc | Sur-binding proteins |
DK2744515T3 (da) | 2011-08-16 | 2022-03-28 | Morphosys Ag | Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep |
SG10201606788VA (en) | 2011-08-16 | 2016-09-29 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a purine analog |
CN102343083A (zh) * | 2011-10-17 | 2012-02-08 | 中国科学院成都生物研究所 | 一种抗病毒的组合药物 |
WO2013067581A1 (en) * | 2011-11-09 | 2013-05-16 | Children's Cancer Institute Australia for Medical Research | Cancer treatment |
ES2710916T3 (es) | 2011-12-22 | 2019-04-29 | I2 Pharmaceuticals Inc | Proteínas de unión sustitutas |
WO2013109994A1 (en) | 2012-01-20 | 2013-07-25 | Sea Lane Biotechnologies, Llc | Surrobody cojugates |
EP2812702B1 (en) | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
JP6423340B2 (ja) | 2012-05-15 | 2018-11-14 | シアトル ジェネティクス,インコーポレイティド | 自己安定化リンカー結合体 |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
IN2014DN10889A (US07794700-20100914-C00152.png) * | 2012-07-13 | 2015-09-11 | Univ Pennsylvania | |
PT2692865E (pt) | 2012-07-30 | 2015-02-06 | Nbe Therapeutics Llc | Identificação mediada por transposição de proteínas funcionais ou de ligação específicas |
MX363385B (es) | 2012-08-23 | 2019-03-20 | Seattle Genetics Inc | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. |
US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
DK2766048T3 (en) | 2012-10-12 | 2015-03-02 | Spirogen Sarl | PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF |
NO2789793T3 (US07794700-20100914-C00152.png) * | 2012-10-24 | 2018-01-27 | ||
DK2911700T5 (en) * | 2012-10-24 | 2017-05-22 | Polytherics Ltd | The drug-protein conjugates |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
EP2928503B1 (en) | 2012-12-10 | 2019-02-20 | Mersana Therapeutics, Inc. | Conjugates of auristatin compounds |
CN105188749B (zh) | 2012-12-21 | 2017-12-19 | 西雅图基因公司 | 抗ntb‑a抗体及相关组合物和方法 |
JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びその結合体 |
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
US9840560B2 (en) * | 2013-03-15 | 2017-12-12 | Alper Biotech Llc | Monoclonal antibodies to EGFR, and uses therefor |
TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
DK3546572T3 (da) * | 2013-05-13 | 2024-05-06 | Cellectis | CD19-specifik kimær antigenreceptor og anvendelser deraf |
CA3187392A1 (en) | 2013-10-15 | 2015-04-23 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
AU2014364812B2 (en) | 2013-12-17 | 2017-05-25 | Novartis Ag | Cytotoxic peptides and conjugates thereof |
EP3104881A4 (en) | 2014-02-11 | 2017-09-27 | Seattle Genetics, Inc. | Selective reduction of proteins |
KR102647074B1 (ko) | 2014-02-17 | 2024-03-14 | 씨젠 인크. | 친수성 항체-약물 컨쥬게이트 |
KR101971770B1 (ko) | 2014-03-03 | 2019-04-24 | 아카데미아 시니카 | 이중특이성 항체 및 이의 용도 |
US9828436B2 (en) | 2014-03-19 | 2017-11-28 | Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital | Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof |
CA2942150A1 (en) * | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
JP2017512801A (ja) * | 2014-04-08 | 2017-05-25 | シアトル ジェネティックス, インコーポレイテッド | Cd19抗体薬物コンジュゲートの最適な投薬 |
SG11201609462RA (en) | 2014-06-13 | 2016-12-29 | Novartis Ag | Auristatin derivatives and conjugates thereof |
WO2016001485A1 (en) | 2014-06-30 | 2016-01-07 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
AU2015312075A1 (en) | 2014-09-03 | 2017-03-09 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
KR20170053648A (ko) | 2014-09-11 | 2017-05-16 | 시애틀 지네틱스, 인크. | 삼차 아민-함유 약물 물질의 표적화된 전달 |
PT3262071T (pt) | 2014-09-23 | 2020-06-16 | H Hoffnabb La Roche Ag | Métodos de utilização de imunoconjugados anti-cd79b |
AP2017009823A0 (en) | 2014-09-26 | 2017-03-31 | Macrogenics Inc | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
EA201791819A1 (ru) * | 2015-02-12 | 2017-12-29 | Сиэтл Дженетикс, Инк. | Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина |
SG11201706786UA (en) | 2015-03-18 | 2017-09-28 | Seattle Genetics Inc | Cd48 antibodies and conjugates thereof |
JP6916741B2 (ja) | 2015-05-26 | 2021-08-11 | モルフォシス・アーゲー | 抗cd19抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 |
CN116726190A (zh) * | 2015-06-20 | 2023-09-12 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
IL303690A (en) | 2015-06-30 | 2023-08-01 | Seagen Inc | Anti–NTB–A antibodies and related preparations and methods |
RS62260B1 (sr) | 2015-08-21 | 2021-09-30 | Morphosys Ag | Kombinacije i njihova upotreba |
EP3347049B1 (en) | 2015-09-08 | 2024-07-03 | Waters Technologies Corporation | Multidimensional chromatography method for analysis of antibody-drug conjugates |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
EP3362472B1 (en) | 2015-10-16 | 2023-08-30 | The Trustees of Columbia University in the City of New York | Compositions and methods for inhibition of lineage specific antigens |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
BR112018016697A2 (pt) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento. |
WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
WO2017165851A1 (en) | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
JP7208010B2 (ja) * | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
ES2878156T3 (es) | 2016-05-30 | 2021-11-18 | Morphosys Ag | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER |
CN109415440B (zh) | 2016-06-27 | 2022-12-06 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
WO2018017928A1 (en) * | 2016-07-22 | 2018-01-25 | Seattle Genetics, Inc. | Combination therapy using a cd19-adc and rchp |
MA45945A (fr) | 2016-08-09 | 2019-06-19 | Seattle Genetics Inc | Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées |
US20180064758A1 (en) * | 2016-09-05 | 2018-03-08 | Ucl Business Plc | Chimeric antigen receptor |
US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
BR112019006778A2 (pt) | 2016-10-18 | 2019-10-15 | Seattle Genetics Inc | Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco |
KR20230028571A (ko) | 2016-10-28 | 2023-02-28 | 모르포시스 아게 | 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 |
JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
CN116672463A (zh) * | 2017-02-17 | 2023-09-01 | 浙江特瑞思药业股份有限公司 | 靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途 |
JP7386082B2 (ja) | 2017-02-28 | 2023-11-24 | ブイオーアール バイオファーマ インコーポレーテッド | 系統特異的タンパク質の阻害のための組成物および方法 |
IL268959B1 (en) | 2017-02-28 | 2024-09-01 | Seagen Inc | Antibodies with cystine mutation, preparations containing them and their uses |
CA3056134A1 (en) | 2017-03-24 | 2018-09-27 | Seattle Genetics, Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
US11931414B2 (en) | 2017-04-27 | 2024-03-19 | Seagen Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US11655307B2 (en) | 2017-05-30 | 2023-05-23 | The Board Of Regents Of The University Of Oklahoma | Anti-doublecortin-like kinase 1 antibodies and methods of use |
KR20200010472A (ko) | 2017-05-31 | 2020-01-30 | 모르포시스 아게 | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 |
US11634488B2 (en) | 2017-07-10 | 2023-04-25 | International—Drug—Development—Biotech | Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics |
CN111051329B (zh) * | 2017-08-10 | 2024-07-30 | 住友制药株式会社 | 哈米特林衍生物及它们的抗体药物复合物 |
PL3666787T3 (pl) | 2017-08-10 | 2024-04-29 | Sumitomo Pharma Co., Ltd. | Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny |
SG11202001817PA (en) * | 2017-09-21 | 2020-03-30 | Wuxi Biologics Ireland Ltd | Novel anti-cd19 antibodies |
CN111201244A (zh) | 2017-10-12 | 2020-05-26 | 学校法人庆应义塾 | 特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
MX2020005640A (es) | 2017-12-01 | 2020-08-20 | Seattle Genetics Inc | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama. |
US11672827B2 (en) * | 2017-12-23 | 2023-06-13 | Uwell Biopharma Inc. | Pharmaceutical chimeric receptor composition and method thereof |
EP3735252A4 (en) * | 2018-01-04 | 2021-10-06 | Avidity Biosciences, Inc. | HETERODUPLEX NUCLEIC ACID MOLECULES AND THEIR USES |
AU2019240403A1 (en) | 2018-03-23 | 2020-10-08 | Seagen Inc. | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
CN112512587A (zh) | 2018-08-06 | 2021-03-16 | 第一三共株式会社 | 抗体药物缀合物和微管蛋白抑制剂的组合 |
EP3844187A1 (en) | 2018-08-28 | 2021-07-07 | Vor Biopharma, Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
WO2020160518A1 (en) * | 2019-02-01 | 2020-08-06 | Memorial Sloan Kettering Cancer Center | Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker |
AU2020219732A1 (en) | 2019-02-05 | 2021-08-05 | Seagen Inc. | Anti-CD228 antibodies and antibody-drug conjugates |
US20220125941A1 (en) * | 2019-02-13 | 2022-04-28 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof |
JP2020132638A (ja) * | 2019-02-13 | 2020-08-31 | 大日本住友製薬株式会社 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
WO2020213084A1 (en) | 2019-04-17 | 2020-10-22 | Keio University | Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof |
WO2020225196A1 (en) | 2019-05-03 | 2020-11-12 | Morphosys Ag | Anti-cd19 therapy in patients having a limited number of nk cells |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
CN110128551A (zh) * | 2019-06-05 | 2019-08-16 | 上海科弈药业科技有限公司 | 一种针对cd19+肿瘤的多功能融合蛋白及其应用 |
TW202112354A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
EP4004046A1 (en) | 2019-07-22 | 2022-06-01 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
AU2020358859A1 (en) | 2019-10-04 | 2022-05-12 | Seagen Inc. | Anti-PD-L1 antibodies and antibody-drug conjugates |
IL292213A (en) | 2019-10-31 | 2022-06-01 | Morphosys Ag | Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cells |
US20210130460A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
CA3161411A1 (en) * | 2019-12-11 | 2021-06-17 | Cullinan Management, Inc. | Anti-serum albumin antibodies |
US20230037815A1 (en) * | 2019-12-11 | 2023-02-09 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
US20230086069A1 (en) * | 2020-03-03 | 2023-03-23 | Systimmune, Inc. | Anti-cd19 antibodies and methods of using and making thereof |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
WO2021207701A1 (en) | 2020-04-10 | 2021-10-14 | Seagen Inc. | Charge variant linkers |
EP4168449A1 (en) | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
EP4192871A1 (en) | 2020-08-04 | 2023-06-14 | Seagen Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
JP2023543026A (ja) | 2020-09-28 | 2023-10-12 | シージェン インコーポレイテッド | がんの処置のためのヒト化抗liv1抗体 |
IL301865A (en) | 2020-10-06 | 2023-06-01 | Xencor Inc | Biomarkers, methods and preparations for the treatment of autoimmune disease, including systemic lupus erythematosus (SLE) |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
IL302402A (en) | 2020-11-08 | 2023-06-01 | Seagen Inc | Combined treatment |
TW202237184A (zh) | 2020-12-04 | 2022-10-01 | 德商莫菲西斯公司 | 抗cd19組合療法 |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
TW202300178A (zh) | 2021-03-18 | 2023-01-01 | 美商西根公司 | 內化的生物活性化合物偶聯物選擇性釋放藥物 |
US20240270842A1 (en) * | 2021-05-07 | 2024-08-15 | Viela Bio, Inc | Use of an anti-cd19 antibody to treat myasthenia gravis |
EP4370211A1 (en) | 2021-07-14 | 2024-05-22 | Seagen Inc. | Antibody masking domains |
EP4405387A1 (en) | 2021-09-24 | 2024-07-31 | Seagen Inc. | Improved antibody masking domains |
WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
WO2023108102A1 (en) * | 2021-12-10 | 2023-06-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Anti-lcn-2 antibodies as a treatment for eye disorders |
US20230381321A1 (en) | 2022-03-17 | 2023-11-30 | Seagan Inc., | Camptothecin conjugates |
JP2023184489A (ja) * | 2022-06-16 | 2023-12-28 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗cd19抗体薬物コンジュゲート |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
WO2024064714A2 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Antibodies that bind cd228 |
WO2024097816A1 (en) | 2022-11-03 | 2024-05-10 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
WO2024165045A1 (en) | 2023-02-09 | 2024-08-15 | Beigene, Ltd. | Self-stabilizing linker conjugates |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5635483A (en) * | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) * | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ES2233928T3 (es) * | 1993-10-01 | 2005-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Derivados de dolastatina. |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
PL199747B1 (pl) * | 1998-04-21 | 2008-10-31 | Micromet Ag | Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T |
DE60122765D1 (de) * | 2000-11-07 | 2006-10-12 | Hope City | Cd19-spezifische umgezielte immunzellen |
CA2443694A1 (en) * | 2001-04-09 | 2002-10-17 | Progenics Pharmaceuticals, Inc. | Anti-cd19 immunotoxins |
US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
LT1507556T (lt) * | 2002-05-02 | 2016-10-10 | Wyeth Holdings Llc | Kalicheamicino darinio ir nešiklio konjugatai |
PT1545613E (pt) | 2002-07-31 | 2011-09-27 | Seattle Genetics Inc | Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa |
EP2100619B1 (en) * | 2003-02-20 | 2014-02-12 | Seattle Genetics, Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders |
DK1613350T3 (da) * | 2003-04-09 | 2009-06-22 | Genentech Inc | Behandling af autoimmun sygdom hos en patient med et utilstrækkeligt respons på en TNF-alfa-inhibitor |
AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US7109304B2 (en) * | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
ES2458636T3 (es) * | 2003-08-18 | 2014-05-06 | Medimmune, Llc | Humanización de anticuerpos |
AU2004316290C1 (en) | 2003-11-06 | 2012-02-02 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP1738343A4 (en) * | 2004-03-08 | 2010-03-24 | Univ Johns Hopkins | DEVICE AND METHOD FOR MEDICAL TRAINING AND EVALUATION |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
NZ580115A (en) * | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
CN1775808A (zh) * | 2004-11-15 | 2006-05-24 | 中国医学科学院血液学研究所 | 用于靶向结合淋巴细胞白血病细胞的抗cd19的工程抗体及其用途 |
KR101335798B1 (ko) * | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-cd19 항체 및 종양학에서 이의 용도 |
US20060263357A1 (en) | 2005-05-05 | 2006-11-23 | Tedder Thomas F | Anti-CD19 antibody therapy for autoimmune disease |
ES2707152T3 (es) * | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
WO2006133450A2 (en) | 2005-06-08 | 2006-12-14 | Duke University | Anti-cd19 antibody therapy for the transplantation |
MX2007015051A (es) * | 2005-06-17 | 2008-01-18 | Wyeth Corp | Metodos para purificar proteinas que contienen la region fc. |
JP5215180B2 (ja) | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Cd19抗体およびその使用法 |
JP5752346B2 (ja) * | 2005-07-18 | 2015-07-22 | シアトル ジェネティックス, インコーポレイテッド | β−グルクロニド−リンカー薬物結合体 |
EP1966245B1 (en) * | 2005-12-30 | 2011-05-18 | Merck Patent GmbH | Anti-cd19 antibodies with reduced immunogenicity |
US20070225595A1 (en) | 2006-01-17 | 2007-09-27 | Don Malackowski | Hybrid navigation system for tracking the position of body tissue |
US20070166306A1 (en) * | 2006-01-17 | 2007-07-19 | Fey Georg H M | Anti-CD19 antibody composition and method |
EP1973947A2 (en) * | 2006-01-20 | 2008-10-01 | Welson Pharmaceuticals, Inc. | Immunoconjugates with improved efficacy for the treatment of diseases |
US20070178103A1 (en) * | 2006-01-30 | 2007-08-02 | Fey Georg H | CD19-specific immunotoxin and treatment method |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2007103288A2 (en) * | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
DK2383297T5 (da) | 2006-08-14 | 2022-07-04 | Xencor Inc | Optimerede antistoffer rettet mod CD19 |
CA2662340C (en) * | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
ES2523915T5 (es) * | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
MX2010004219A (es) | 2007-10-19 | 2010-08-09 | Seattle Genetics Inc | Agentes de enlace de cd19 y usos de los mismos. |
CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
-
2008
- 2008-10-17 MX MX2010004219A patent/MX2010004219A/es active IP Right Grant
- 2008-10-17 CA CA2702555A patent/CA2702555A1/en active Pending
- 2008-10-17 DK DK08840713.5T patent/DK2211904T3/en active
- 2008-10-17 EP EP08840713.5A patent/EP2211904B1/en active Active
- 2008-10-17 CN CN200880122233.1A patent/CN101903403B/zh active Active
- 2008-10-17 US US12/253,895 patent/US7968687B2/en active Active
- 2008-10-17 ES ES08840713.5T patent/ES2599172T3/es active Active
- 2008-10-17 SI SI200831686A patent/SI2211904T1/sl unknown
- 2008-10-17 PT PT88407135T patent/PT2211904T/pt unknown
- 2008-10-17 JP JP2010530159A patent/JP5727786B2/ja active Active
- 2008-10-17 AU AU2008311815A patent/AU2008311815B2/en active Active
- 2008-10-17 WO PCT/US2008/080373 patent/WO2009052431A2/en active Application Filing
- 2008-10-17 PL PL08840713T patent/PL2211904T3/pl unknown
- 2008-10-17 KR KR1020107010490A patent/KR101658083B1/ko active IP Right Grant
- 2008-10-17 LT LTEP08840713.5T patent/LT2211904T/lt unknown
- 2008-10-17 HU HUE08840713A patent/HUE031533T2/hu unknown
- 2008-10-17 RU RU2010115886/10A patent/RU2476441C2/ru active
-
2010
- 2010-10-18 HK HK10109867.9A patent/HK1143321A1/zh unknown
-
2011
- 2011-05-17 US US13/109,957 patent/US8242252B2/en active Active
-
2012
- 2012-06-21 US US13/530,074 patent/US9073993B2/en active Active
-
2015
- 2015-01-09 JP JP2015002756A patent/JP2015129131A/ja active Pending
- 2015-06-18 US US14/743,318 patent/US9919061B2/en active Active
-
2016
- 2016-10-14 HR HRP20161345TT patent/HRP20161345T1/hr unknown
- 2016-11-16 CY CY20161101174T patent/CY1118349T1/el unknown
-
2018
- 2018-02-14 US US15/897,063 patent/US11331394B2/en active Active
-
2022
- 2022-03-08 US US17/689,388 patent/US20230033859A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161345T1 (hr) | Cd19 vezivna sredstva i njihova uporaba | |
WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
HRP20201790T1 (hr) | Konjugati cisteinom izmijenjenih antitijela | |
CN105849086B (zh) | 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用 | |
CN108026123B (zh) | 用于偶联的亲水链接体 | |
CN106414465B (zh) | 带电荷链接体及其在共轭反应上的应用 | |
JP2011500725A5 (US07794700-20100914-C00152.png) | ||
JP2019142928A (ja) | 細胞傷害性ベンゾジアゼピン誘導体 | |
JP2021534124A (ja) | 癌治療用ptpn11(shp2)阻害剤としての6−(4−アミノ−3−メチル−2−オキサ−8−アザスピロ[4.5]デカン−8−イル)−3−(2,3−ジクロロフェニル)−2−メチルピリミジン−4(3h)−オン誘導体及び関連化合物 | |
SI2906296T1 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
CA2494105A1 (en) | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | |
JP2009501800A5 (US07794700-20100914-C00152.png) | ||
RU2694688C2 (ru) | АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
SI2582728T1 (en) | Human Antibodies Conjugates against a Tissue Factor | |
BR0008173A (pt) | Composto de amida e seu uso como campo técnico de medicina da invenção | |
SI9620111B (en) | Imidazole derivatives having affinity for alpha2 receptors activity | |
CA2429781A1 (en) | Linkable sialyl lewis x analogs | |
CA3044621A1 (en) | Method of treating focal segmental glomerulosclerosis | |
CN114040778A (zh) | 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法 | |
DE602007010625D1 (de) | Pharmazeutische zusammensetzung zur injektion, insbesondere zur gezielten lokalen anwendung | |
CA3236949A1 (en) | Drug conjugates and methods of preparing and using the same | |
WO2024155761A1 (en) | Drug conjugates and methods of preparing and using the same | |
WO2024127332A1 (en) | Cytotoxic compounds | |
TW202430562A (zh) | Bcma單株抗體及抗體藥物結合物 | |
WO2024127333A1 (en) | Cytotoxic compounds |